TheEdgeResearch
Home / Stocks / AKYA

Akoya Biosciences, Inc. (AKYA)

NASDAQ Healthcare Medical - Instruments & Supplies
$1.29 ▼ -5.15%
Market Cap
$64.4M
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
1.35
52-Wk Range
0.931-3.42
CEO
Brian McKelligon
Country
US
Currency
USD

Akoya Biosciences, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Marlborough, MA, US. The stock last traded at $1.29, down 5.15% on the session, giving a market capitalisation of $64.4M. On trailing twelve-month figures it carries a trailing P/E of -1.15, a net margin of -67.8%. Its beta of 1.35 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-1.15
Price / Sales
0.79
Price / Book
8.39
EV / EBITDA
-3.68
Gross margin
58.6%
Operating margin
-57.2%
Net margin
-67.8%
Return on equity
Debt / equity
11.08
Current ratio
2.61
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
205
IPO date
2021-04-16
Headquarters
Marlborough, MA, US
About Akoya Biosciences, Inc.

Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.

Comparable companies

Akoya Biosciences, Inc. is most often compared with the following Healthcare names:

ACHLHTBXLFWDNEUEOMICRPHMSGTXSURFVLNSZYNE
More research on AKYA
AKYA technical analysis AKYA TheEdge Score Compare against peers
Open full interactive analysis & DCF →